<!doctype html>
<html class="no-js" lang="en">
  <head>
    <meta charset="utf-8">
		<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=0, minimum-scale=1.0, maximum-scale=1.0">
    <meta name="format-detection" content="telephone=no">
		<title>Efficacy</title>
    <link rel="stylesheet" href="../shared/css/foundation.css" type="text/css">
    <link rel="stylesheet" href="../shared/css/global.css" type="text/css">
    <link rel="stylesheet" href="css/slide.css" type="text/css">
    <script type="text/javascript" src="../shared/js/vendor/modernizr.js"></script>
  </head>
  <body id="C05" class="subpage" data-trace="trace_c05-mono_landing.jpg" data-overlay-trace="trace_c05_adj_results-overlay.jpg">
		<main class="slide">
      <div class="row collapse">
        <section class="columns">
          <nav id="header-nav" class="row"></nav>
          <article class="row landscape">
            <h2 class="left">Efficacy</h2>
            <ul class="tabs" data-tab>
              <li class="tab-title active">
                <a href="#adj_tab" aria-selected="true">Adjunctive Therapy</a>
              <li class="tab-title">
                <a href="#mono_tab">Monotherapy</a>
              </li>
            </ul>
            <div class="tabs-content">
              <section class="content active relative" id="adj_tab">
                <figure class="panel callout" data-bg>
                  <div>
                    <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>effective seizure reduction <br>as adjunctive therapy</h1>
                  </div>
                </figure>
                <div data-tabbed="adj_landing" class="tabbed-content active">
                  <h3>APTIOM adjunctive therapy was studied in 3 separate randomized, double-blind, placebo-controlled, multicenter studies&sup1;</h3>
                  <ul class="disc">
                    <li>Patients were adults with partial-onset seizures with or without secondary generalization inadequately <br>controlled on 1–3 concomitant AEDs&sup1;
                      <ul>
                        <li>Patients had a median duration of epilepsy of 19 years; 69% were using 2 concomitant AEDs, 28% were <br>using 1 concomitant AED</li>
                      </ul>
                    </li>
                  </ul>
                  <h4>Most commonly used concomitant AED<span class="lowercase">s</span> in clinical trial patients&sup1;</h4>
                  <table>
                    <thead>
                      <tr>
                        <th>Carbamazepine</th>
                        <th>Lamotrigine</th>
                        <th>Valproic acid</th>
                        <th>Levetiracetam</th>
                      </tr>
                    </thead>
                    <tfoot>
                      <tr>
                        <td colspan="4">
                          <ul class="disc">
                            <li>Oxcarbazepine was not allowed as a concomitant AED&sup1;</li>
                          </ul>
                        </td>
                      </tr>
                    </tfoot>
                    <tbody>
                      <tr>
                        <td>50%</td>
                        <td>24%</td>
                        <td>21%</td>
                        <td>18%</td>
                      </tr>
                    </tbody>
                  </table>
                  <h4>Study Design</h4>
                  <ul class="disc">
                    <li>Patients were randomly assigned to placebo or APTIOM 400 mg, 800 mg, or 1200 mg once daily <br>(APTIOM 400 mg was evaluated only in Studies 3 and 4 and did not show a significant treatment effect)&sup1;</li>
                    <li>Following a 2-week titration phase, patients remained on a stable dose of APTIOM or placebo for <br>a 12-week maintenance phase&sup1;</li>
                    <li><b>Primary efficacy endpoint in all 3 studies:</b> standardized seizure frequency per 4 weeks during 12 weeks <br>of maintenance therapy (seizure frequency per 28 days)&sup1;</li>
                    <li><b>Efficacy and safety populations:</b> 1410 and 1447 patients, respectively&sup2;</li>
                  </ul>
                  <nav class="tabbed-nav">
                    <button class="button tabbed" href="#adj_results" data-tabbed-id="adj_results">Results&nbsp;<img class="right" alt="" src="../shared/img/caret.svg"></button>
                  </nav>
                </div>
                <div data-tabbed="adj_results" class="tabbed-content">
                  <h3>Standardized seizure frequency per 4 weeks during 12 weeks of maintenance therapy was significantly lower with APTIOM vs&nbsp;placebo (<i>P</i>&lt;0.05; primary endpoint)&sup1;</h3>
                  <ul class="disc">
                    <li>A statistically significant effect was observed with APTIOM 800 mg in Studies 3 and 4 (Study 5; <i>P</i>=0.058), and with APTIOM 1200 mg in all 3 studies&sup1;</li>
                  </ul>
                  <h4>SECONDARY ENDPOINT&mdash;PROPORTION OF PATIENTS BY CATEGORY OF SEIZURE REDUCTION FOR APTIOM AND PLACEBO ACROSS ALL 3 DOUBLE-BLIND STUDIES<sup>*</sup>&sup1;<sup>,</sup>&sup2;</h4>
                  <figure class="chart">
                    <a class="block relative" data-reveal-id="modal-adj_results">
                      <img alt="" src="img/chart-secondary_endpoint.svg" width="622">
                      <img src="../shared/img/icon_zoom.svg" class="icon_zoom" alt="">
                    </a>
                    <figcaption>
                      <ul class="asterisk">
                        <li>Response was defined as &ge;50% reduction in standardized seizure frequency. Patients in APTIOM clinical studies experienced a range of treatment effects from no response (an increase from baseline in seizure frequency to a modest reduction from baseline in seizure frequency) to a 100% reduction from baseline in seizure frequency.&sup2;</li>
                      </ul>
                      <ul class="disc">
                        <li>Up to 16% of patients taking APTIOM had 75% to 100% seizure reduction&sup2;</li>
                      </ul>
                    </figcaption>
                  </figure>
                  <nav class="tabbed-nav">
                    <button class="button tabbed" href="#adj_landing" data-tabbed-id="adj_landing" rel="landing" role="back"><img class="right" alt="" src="../shared/img/caret.svg"></button>
                  </nav>
                </div>
                <aside data-isi-link></aside>
              </section>
              <section class="content relative" id="mono_tab">
                <figure class="panel callout" data-bg>
                  <div>
                    <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>proven effective as monotherapy</h1>
                  </div>
                </figure> 
                <div data-tabbed="mono_landing" class="tabbed-content active">
                  <img src="img/logo-aed.svg" id="logo-aed" alt="" class="absolute">
                  <h3>APTIOM monotherapy was studied in 2 identical dose-blinded, <br>historical-control studies&sup1;</h3>
                  <ul class="disc">
                    <li>Patients were adults with partial-onset seizures with or without secondary generalization inadequately <br>controlled by 1 or 2 baseline AEDs&sup1;<sup>,</sup>&sup2;
                      <ul>
                        <li>Both baseline AEDs could not be sodium channel–blocking drugs, and at least 1 AED was limited to <br>2/3 of a typical dose</li>
                      </ul>
                    </li>
                  </ul>
                  <h4>Most Common Baseline AED<span class="lowercase">s</span> in APTIOM Monotherapy Studies&sup2;</h4>
                  <table>
                    <thead>
                      <tr>
                        <th>Carbamazepine</th>
                        <th>Levetiracetam</th>
                        <th>Valproic acid</th>
                        <th>Lamotrigine</th>
                      </tr>
                    </thead>
                    <tfoot>
                      <tr>
                        <td colspan="4">
                          <ul class="disc">
                            <li>7% of patients were taking oxcarbazepine at baseline&sup1;</li>
                          </ul>
                        </td>
                      </tr>
                    </tfoot>
                    <tbody>
                      <tr>
                        <td>27%</td>
                        <td>25%</td>
                        <td>20%</td>
                        <td>15%</td>
                      </tr>
                    </tbody>
                  </table>
                  <h4>Study Design</h4>
                  <ul class="disc">
                    <li>Following a 2-week titration phase, baseline AEDs were gradually tapered over a 6-week withdrawal <br>phase. Patients remained on a stable dose of APTIOM 1600 mg or 1200 mg for a 10-week <br>monotherapy phase&sup1;</li>
                    <li><b>Primary efficacy endpoint in both studies:</b> Kaplan-Meier (K-M) estimate of the cumulative exit rate at <br>16 weeks (from beginning of the 6-week AED withdrawal phase to end of the 10-week APTIOM <br>monotherapy phase) based on predefined exit criteria&sup1;</li>
                    <li><b>Efficacy and safety populations:</b> 332 and 365 patients, respectively&sup2;</li>
                  </ul>
                  <nav class="tabbed-nav">
                    <button class="button tabbed" href="#mono_exit" data-tabbed-id="mono_exit">Exit Criteria&nbsp;<img class="right" alt="" src="../shared/img/caret.svg"></button>
                  </nav>
                </div>
                <div data-tabbed="mono_exit" class="tabbed-content">
                  <h4>PREDEFINED EXIT CRITERIA INDICATING AN INCREASE IN SEIZURE FREQUENCY OR SEVERITY&sup1;</h4>
                  <h5>Exit required &ge;1 of the following&sup1;:</h5>
                  <dl class="row">
                    <dt>Status epilepticus</dt>
                    <dd>1 episode</dd>
                  </dl>
                  <dl class="row">
                    <dt>Generalized tonic-clonic seizure</dt>
                    <dd>Emergence in patients who had not had one in the past 6 months</dd>
                  </dl>
                  <dl class="row">
                    <dt>28-day seizure rate</dt>
                    <dd>Doubling of average monthly seizure count during any 28 consecutive days</dd>
                  </dl>
                  <dl class="row" data-equalizer="seizure-rate">
                    <dt data-equalizer-watch="seizure-rate">2-day seizure rate</dt>
                    <dd data-equalizer-watch="seizure-rate">Doubling of highest consecutive 2-day seizure frequency during <br>the entire treatment phase*</dd>
                  </dl>
                  <dl class="row" data-equalizer="seizure-severity">
                    <dt data-equalizer-watch="seizure-severity">Seizure severity</dt>
                    <dd data-equalizer-watch="seizure-severity">Worsening of seizure severity considered by the investigator <br>to require intervention</dd>
                  </dl>
                  <ul class="asterisk">
                    <li>If the highest number of seizures in a consecutive 2-day period was 1, 3 seizures in a consecutive 2-day period <br>were required to exit.&sup2;</li>
                  </ul>
                  <ul class="disc">
                    <li><b>Primary efficacy endpoint in both studies:</b> Kaplan-Meier (K-M) estimate of the cumulative exit rate at <br>16 weeks (from beginning of the 6-week AED withdrawal phase to end of the 10-week APTIOM <br>monotherapy phase) based on predefined exit criteria&sup1;</li>
                  </ul>
                  <nav class="tabbed-nav">
                    <button class="button tabbed" href="#mono_landing" data-tabbed-id="mono_landing" rel="landing" role="back"><img alt="" src="../shared/img/caret.svg"></button>
                    <button class="button tabbed" href="#mono_results" data-tabbed-id="mono_results">Results&nbsp;<img class="right" alt="" src="../shared/img/caret.svg"></button>
                  </nav>
                </div>
                <div data-tabbed="mono_results" class="tabbed-content">
                  <h3>Lower exit rates were demonstrated with APTIOM <br>1200 mg and 1600 mg monotherapy vs historical control&sup1;<sup>,</sup>&sup3;</h3>
                  <ul class="disc">
                    <li>Effectiveness was established if the upper limit of the 95% confidence interval of the exit rate was &lt;65% (the lower <br>limit of the 95% prediction interval for the exit rate in the pseudo-placebo arms) derived from the historical-control data&sup1;</li>
                  </ul>
                  <h4>PERCENT OF PATIENTS MEETING &ge;1 EXIT CRITERIA WITH APTIOM 1200 <span class="lowercase">mg</span> OR 1600 <span class="lowercase">mg</span> MONOTHERAPY <br>(K-M ESTIMATES)&sup1;<sup>,</sup>&sup3;</h4>
                  <figure class="chart relative">
                    <a class="block relative" data-reveal-id="modal-mono_results">
                      <img alt="" src="img/chart-exit_criteria.svg" width="613">
                      <ul class="absolute" data-step-animated rel="exit_criteria">
                        <li class="transparent"><img alt="" src="../shared/img/icon_check.svg" width="17"></li>
                        <li class="transparent"><img alt="" src="../shared/img/icon_check.svg" width="17"></li>
                        <li class="transparent"><img alt="" src="../shared/img/icon_check.svg" width="17"></li>
                        <li class="transparent"><img alt="" src="../shared/img/icon_check.svg" width="17"></li>
                      </ul>
                      <img src="../shared/img/icon_zoom.svg" class="icon_zoom" alt="">
                    </a>
                    <figcaption>
                      <ul class="disc">
                        <li>The upper limits of the 95% confidence interval of both doses in both studies were below the threshold of 65% derived <br>from the historical-control data, meeting the prespecified criteria for efficacy&sup1;</li>
                      </ul>
                    </figcaption>
                  </figure>
                  <nav class="tabbed-nav">
                    <button class="button tabbed" href="#mono_exit" data-tabbed-id="mono_exit" rel="exit" role="back"><img alt="" src="../shared/img/caret.svg"></button>
                  </nav>
                </div>
                <aside data-isi-link></aside>
              </section>
            </div>
          </article>
          <article class="row portrait"></article>
        </section>
        <aside id="sidebar" class="columns"></aside>
      </div>
		</main>
		<footer id="footer-menu" class="footer-menu landscape"></footer>
    <div id="modals"></div>
    <div id="modal-adj_results" data-reveal class="reveal-modal full" aria-labelledby="modal-adj_results-title" aria-hidden="true" role="dialog">
      <h3 id="modal-adj_results-title" class="blue">SECONDARY ENDPOINT&mdash;PROPORTION OF PATIENTS BY CATEGORY OF SEIZURE REDUCTION FOR APTIOM AND&nbsp;PLACEBO ACROSS ALL 3 DOUBLE-BLIND STUDIES<sup>*</sup>&sup1;<sup>,</sup>&sup2;</h3>
      <figure>
        <img alt="" src="img/chart-secondary_endpoint.svg" width="100%">
        <figcaption>
          <ul class="asterisk">
            <li>Response was defined as &ge;50% reduction in standardized seizure frequency. Patients in APTIOM clinical studies experienced a range of treatment effects from no response (an increase from baseline in seizure frequency to a modest reduction from baseline in seizure frequency) to a 100% reduction from baseline in seizure frequency.&sup2;</li>
          </ul>
        </figcaption>
      </figure>
      <a class="close-reveal-modal" aria-label="Close">&#215;</a>
    </div>
    <div id="modal-mono_results" data-reveal class="reveal-modal full" aria-labelledby="modal-mono_results-title" aria-hidden="true" role="dialog">
      <h3 id="modal-mono_results-title" class="blue">PERCENT OF PATIENTS MEETING &ge;1 EXIT CRITERIA WITH APTIOM 1200 mg OR 1600 mg MONOTHERAPY <br>(K-M ESTIMATES)&sup1;<sup>,</sup>&sup3;</h3>
      <figure class="relative">
        <img alt="" src="img/chart-exit_criteria.svg" width="100%">
        <ul class="absolute" rel="modal-exit_criteria">
          <li><img alt="" src="../shared/img/icon_check.svg" width="17"></li>
          <li><img alt="" src="../shared/img/icon_check.svg" width="17"></li>
          <li><img alt="" src="../shared/img/icon_check.svg" width="17"></li>
          <li><img alt="" src="../shared/img/icon_check.svg" width="17"></li>
        </ul>
        <figcaption>
          <ul class="disc">
            <li>The upper limits of the 95% confidence interval of both doses in both studies were below the threshold of 65% derived from the historical-control data, meeting the prespecified criteria for efficacy&sup1;</li>
          </ul>
        </figcaption>
      </figure>
      <a class="close-reveal-modal" aria-label="Close">&#215;</a>
    </div>
    <script type="text/javascript" src="../shared/js/vendor/jquery.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/veeva-library-4.2.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/ivaHelper-1.0.1.js"></script>
    <script type="text/javascript" src="../shared/js/foundation.min.js"></script>
    <script type="text/javascript" src="../shared/js/foundation/foundation.equalizer.js"></script>
    <script type="text/javascript" src="../shared/js/foundation/foundation.reveal.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/jquery.touchSwipe.min.js"></script>
		<script type="text/javascript" src="../shared/js/vendor/iscroll.js"></script>
    <script type="text/javascript" src="../shared/js/global.js"></script>
    <script type="text/javascript" src="js/slide.js"></script>
  </body>
</html>